News
-
-
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Mainz Biomed partners with TomaLab to expand ColoAlert® availability in Italy, enhancing colorectal cancer screening. Collaboration brings advanced DNA technology for early detection to Italian healthcare -
COMMUNIQUÉ DE PRESSE
MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
Mainz Biomed N.V. (NASDAQ:MYNZ) has established the 'European Oncology Lab' (EOL), a physician-led laboratory for expanding service offering to privately insured patients in Germany. The lab will offer ColoAlert® as a laboratory medical service directly to physicians and patients, addressing the crucial requirement for invoicing private health insurance companies -
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
-
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
